Building a Better Vector: The Manipulation of AAV Virions
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
This review will focus on research directed at manipulating the virion of adeno-associated virus (AAV) with the goals of circumventing the immune response of the virion, as well as retargeting the virus to specific cell types of interest. The use of five AAV serotypes for addressing questions of Ab neutralization, novel tropism, as well as providing natural templates for targeting by virion modification will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684 · cited 1×
“…of the population with seropositive antibodies against AAV type 2 between 50 and 96%, with 18 to 67.5% being neutralizing (Blacklow et al., 1968; Chirmule et al., 1999; Erles et al., 1999; Moskalenko et al., 0042-6822/00 $35.00 Copyright © 0 by Academic Press All rights of reproduction in any…”
BackgroundInfluentialRecombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654 · cited 2×
“In experimental animals, neutralizing antibodies have been shown to eliminate (Fisher et al., 1997; Kessler et al., 1996; Xiao et al., 1996) or greatly reduce (Chirmule t al., 2000; Xiao et al., 2000) the levels of transgene xpression of the readministered vector.”
BackgroundGene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532
Self-citationDavidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531 · cited 1×
“In another report comparing AAV serotypes 2, 4, and 5 in vivo, investigators observed different regional distribution and transduction efficiency in the central nervous system at three and fifteen weeks after injection (Davidson et al., 2000).”
Jooss, K., Yang, Y., Fisher, K. J., & Wilson, J. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4212-4223.1998 · Cited by 470
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405
Chao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366 · cited 1×
“The serotype-specific tropism provides the unique opportunity for transducing distinct cell types in vivo more efficiently Chao et al., 2000).”
BackgroundSelf-citationAdeno-associated virus general transduction vectors: analysis of proviral structures
McLaughlin, S. K., Collis, P., Hermonat, P. L., & Muzyczka, N. (1988) · Journal of Virology · doi:10.1128/jvi.62.6.1963-1973.1988 · Cited by 348 · cited 1×
“These terminal repeats are reuired for the replication and packaging of the recombiant genome into the newly formed AAV virions McLaughlin et al., 1988; Samulski et al., 1989).”
BackgroundMoskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., & Patel, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1761-1766.2000 · Cited by 253
Cited by
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612
Opie, S. R., Warrington, Agbandje-McKenna, M., Zolotukhin, S., & Muzyczka, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.6995-7006.2003 · Cited by 364
Girod, A., Wobus, C. E., Zádori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J. A., & Hallek, M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-5-973 · Cited by 354
“The capsid consists of three structural proteins, VP1, VP2 and VP3, in a ratio of 1 :1 :20, which are expressed from the same open reading frame by using alternative splicing and an atypical start codon (reviewed by Berns & Giraud, 1996 ; Rabinowitz & Samulski, 2000).”
BackgroundVarious AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy
Jooss, K., & Chirmule, N. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302037 · Cited by 277
Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy
Ito, H., Koefoed, M., Tiyapatanaputi, P., Gromov, K., Goater, J. J., Carmouche, J., Zhang, X., Rubery, P. T., Rabinowitz, J., Samulski, R. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1190 · Cited by 274
Self-citationAdeno-associated virus: from defective virus to effective vector
Gonçalves, M. A. (2005) · Virology Journal · doi:10.1186/1743-422x-2-43 · Cited by 264
Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
Self-citationControlling AAV Tropism in the Nervous System with Natural and Engineered Capsids
Castle, M. J., Turunen, H. T., Vandenberghe, L. H., & Wolfe, J. H. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_10 · Cited by 151
“Hybrid capsids are designed to harness the structural similarity among AAVs, combining beneficial properties from two or more different serotypes by co-expressing their capsid proteins during vector production [68].”
BackgroundXin, K.-Q., Mizukami, H., Urabe, M., Toda, Y., Shinoda, K., Yoshida, A., Oomura, K., Kojima, Y., Ichino, M., Klinman, D., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00890-06 · Cited by 81
“Of note, while we used a prime/boost regimen involving repeated administration of the same AAV serotype vector, it may be even more effective to prime with one serotype and boost with another (since neutralizing Abs raised against the first vector are unlikely to cross-react with a different serotype) (48).”
MethodExpression of Human Factor VIII by Splicing between Dimerized AAV Vectors
Chao, H., Sun, L., Bruce, A., Xiao, X., & Walsh, C. E. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0607 · Cited by 75
Kitajima, K., Marchadier, D. H. L., Miller, G. C., Gao, G.-P., Wilson, J. M., & Rader, D. J. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000231520.26490.54 · Cited by 54
Peden, C. S., Manfredsson, F. P., Reimsnider, S. K., Poirier, A. E., Burger, C., Muzyczka, N., & Mandel, R. J. (2009) · Molecular Therapy · doi:10.1038/mt.2008.284 · Cited by 44
Metadata
- Authors
- Rabinowitz, J. E., & Samulski, R. J.
- Venue
- Virology
- Publisher
- Elsevier BV
- Published
- 2000-12
- Volume
- 278
- Issue
- 2
- Pages
- 301-308
- ISSN
- 0042-6822 (ISSN-L)
- OpenAlex
- W2086683565
- Cited by
- 117
- References
- 17
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.